Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Novo Nordisk manufactures semaglutide, which is prescribed under the brand names Ozempic (approved for diabetes) and Wegovy ...

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...

SMITHTOWN, NY, UNITED STATES, April 4, 2025 /EINPresswire / -- The rise of weight-loss medications like Ozempic, Wegovy, and Mounjaro has transformed bodies-and unexpectedly, faces. As thousands ...

Ozempic improved maximum walking distance by 13% in peripheral artery disease patients over 52 weeks. Rybelsus reduced the risk of major cardiovascular events by 14% in high-risk patients.

As in my article "AbbVie vs. Sanofi: Which Is the Better Investment ... and psoriatic arthritis treatment market. They are Ozempic, Wegovy, Rybelsus, NovoRapid, and NovoSeven, whose combined ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial 1.